Subsidy for CGRP inhibitor 'a milestone'

Thousands of patients are expected to benefit, a neurologist says

The first calcitonin gene-related peptide (CGRP) inhibitor to be PBS listed will prompt reassessment for many patients severely affected by migraine, a leading neurologist says.

Man in bed with a migraine

Associate Professor Richard Stark, from the Alfred Hospital in Melbourne, said the listing of galcanezumab (Emgality, Eli Lilly) from 1 June for patients with chronic migraine was a “tremendous milestone”.

“This … will prompt the reassessment of a large number of patients at the severe end of